drugset / Trial / NCT06825494
Clinical Studies for the Treatment of Advanced Solid Tumors
Phase 1/2
Recruiting
194 enrolled
Chia Tai Tianqing Pharmaceutical Group Nanjing Shunxin Pharmaceutical Co., Ltd.
RandomizedParallel-groupOpen-labelTreatment
Summary
This trial is part of a multicenter, open-label Phase Ib/II clinical study evaluating the efficacy, safety, and tolerability of LM-108 in combination with anti-tumor therapy in patients with advanced solid tumors. Phase Ib of Cohort A1 determines the dose of LM-108 in combination with penpulimab + oxaliplatin + capecitabine. Phase II explores the efficacy and safety of LM-108 in combination with anti-tumor therapy in patients with advanced solid tumors.
Timeline
- Start
- 2025-04-08
- Primary completion
- 2026-03
- Completion
- 2026-09
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | CAFELKIBART | Monoclonal antibody | 10 mg/kg | Intravenous |
| Subject | CAFELKIBART | Monoclonal antibody | 600 mg | Intravenous |
| Subject | Tislelizumab | Monoclonal antibody | — | Intravenous |
| Background | Capecitabine | Small molecule | 2000 mg/m2 | Oral |
| Background | Oxaliplatin | Small molecule | — | Intravenous |
| Background | Penpulimab | Monoclonal antibody | — | Intravenous |